Abstract
Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Co...Continue Reading
Citations
Aug 27, 2019·Expert Review of Anticancer Therapy·Giulia VialeGiuseppe Curigliano
Apr 8, 2020·World Journal of Clinical Oncology·Sylwan RahardjaElaine Hsuen Lim
Jun 24, 2020·JCO Oncology Practice·Francesca PoggioMatteo Lambertini
Oct 23, 2019·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Aug 12, 2020·Breast Cancer Research and Treatment·Yada KanjanapanLaeeq Malik
Nov 22, 2019·Frontiers in Oncology·Tamara Díaz-RedondoEmilio Alba
May 6, 2020·The Oncologist·Hossein TaghizadehGerald W Prager
Jun 6, 2020·Frontiers in Genetics·Minfeng LiuZhaoze Guo
Oct 7, 2020·Drugs·Megan E Tesch, Karen A Gelmon
Oct 22, 2020·Cell Death Discovery·Olga FedorovaNikolai Barlev
Apr 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·William J GradisharRashmi Kumar
Nov 12, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Paul CottuXavier Pivot
Dec 2, 2020·Biochimica Et Biophysica Acta. Reviews on Cancer·Paolo TarantinoGiuseppe Curigliano
Jan 28, 2021·The Annals of Otology, Rhinology, and Laryngology·Guy TalmorChristen Caloway